No. of Recommendations: 2
Date What Actually Happened
11/13/23 CLEAR Outcomes results
12/13/23 FDA updates to include Primary prevention
1/3/24 DSE and Esperion settle lawsuit
1/18/24 Esperion dilution occurs
2/27/24 4Q-23 ER, 39% y/y US sales growth
2/27/24 4Q-23 ER, 43% y/y US SCRIPT growth
3/22/24 FDA approves broad new labels
5/7/24 1Q-24 ER, 46% y/y US sales growth
5/7/24 1Q-24 ER, 43% y/y US SCRIPT growth
5/14/24 Patent extended 5 years
5/20/24 Phase 3 Japan ends successfully
5/22/24 Europe label updated to include Primary
6/1/24 1st wave of Payers improve UM/coverage
6/28/24 OMERS (DSE royalties) deal/payoff RIPA Debt
8/12/24 2Q-24 ER, 39% y/y US sales growth
8/12/24 2Q-24 ER, 43% y/y US SCRIPT growth
9/3/24 2nd Wave of Payer improvements announced
10/2/24 DSE reports final 2-yr positive study data
10/31/24 AHA presos on PAD and Liver
11/7/24 3Q-24 ER, 53% y/y US sales growth
11/7/24 3Q-24 ER, 47% y/y US SCRIPT growth
11/18/24 CLEAR Outcomes positive results/patients with PAD
11/26/24 OTSUKA files to sell BA in Japan as expected
12/2/24 Esperion files to sell BA in Canada (new mkt)
12/2/24 Esperion partners w Neopharm for Israel (new mkt)
12/13/24 Notes due 11/25; refinanced to 2030
